===
EQS-News: Dermapharm Holding SE / Key word(s): AGM/EGM
Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share
2024-06-27 / 18:15 CET/CEST
The issuer is solely responsible for the content of this announcement.
Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share

. 2024 outlook confirmed
. Board of Management and Supervisory Board actions ratified with large majority
. Shareholders resolve dividend payment of EUR 0.88 per share
. Distribution ratio: approximately 78% of consolidated net profit

Grünwald, 27 June 2024 - Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded
pharmaceuticals and other healthcare products, today held its Annual General Meeting for financial year 2024. 90.3% of
the share capital was in attendance at the Annual General Meeting, which was held in person. The majority of
shareholders approved the management's proposals under every agenda item.
The Annual General Meeting ratified the actions of all members of the Board of Management and of the Supervisory Board
for financial year 2023 with a 98.6% and 91.5% majority of votes cast, respectively. The Annual General Meeting acted
on the recommendation of the Board of Management and the Supervisory Board to distribute a dividend of EUR 0.88 per
share carrying dividend rights. The total distribution amounts to EUR 47.4 million, representing a distribution ratio
of approximately 78% of the distributable consolidated net income.
Grant Thornton AG Wirtschaftsprüfungsgesellschaft was re-elected as the auditor for the current financial year. RSM
Ebner Stolz GmbH & Co. KG Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft was chosen as auditor for the
sustainability reporting. The detailed results of the voting for each agenda item are available in the Annual General
Meeting section of the Company website https://ir.dermapharm.de.
In their retrospective on financial year 2023, the Board of Management and Supervisory Board emphasised the particular
strength and resilience of the corporate strategy. Dermapharm succeeded in maintaining its growth trajectory despite a
difficult macroeconomic environment and the scheduled end of vaccine production. The Board of Management and the
Supervisory Board expressed their special thanks to the entire workforce for their extraordinary dedication and
commitment. The Board of Management concluded by providing an outlook for the remainder of financial year 2024.
"We have used 2023 to make the company fit for the future. The investment in the acquisition of Arkopharma and Montavit
is a booster for our internationalisation. With targeted investments in photovoltaics and energy efficiency
improvements, for example, we are able to reduce costs and offer our customers a sustainable supply of pharmaceuticals
made in Europe," said Dr. Hans-Georg Feldmeier, CEO of Dermapharm Holding SE.
Based on the course of business to date in 2024, the Board of Management confirms the guidance for 2024 and expects
consolidated revenue of EUR 1,170-1,210 million and adjusted consolidated EBITDA of EUR 305-315 million.

Company profile
Dermapharm - Pharmaceutical Excellence "Made in Europe"
Dermapharm is an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products.
Founded in 1991, the Company is based in Grünwald near Munich. In addition to its main location in Brehna near Leipzig,
Dermapharm also operates other production, development and distribution locations in Germany, the rest of Europe and
the United States.
In the "Branded pharmaceuticals" segment, Dermapharm has more than 1,300 marketing authorisations with more than 400
active pharmaceutical ingredients. Dermapharm's portfolio of pharmaceuticals is tailored to selected therapeutic areas
in which the Company is a market leader, especially in Germany. The Company's integrated business model extends from
in-house product development and production through quality management and logistics to the distribution of branded
pharmaceuticals by a trained pharmaceutical sales force.
Dermapharm bundles food supplements, herbal pharmaceuticals, cosmetics, medical devices, herbal extracts and medicinal
cannabis in its "Other healthcare products" segment. In this segment, Dermapharm can tap the expertise of Arkopharma,
the market leader for herbal food supplements in France, and the Spanish company Euromed S.A., a leading global
manufacturer of herbal extracts and plant-based active ingredients for the pharmaceuticals, nutraceuticals, foodstuffs
and cosmetics industries.
Dermapharm also operates the "Parallel import business" segment under the axicorp brand. axicorp imports originator
pharmaceuticals from other EU Member States and resells them to pharmaceuticals wholesalers and pharmacies in Germany.
This enables axicorp to benefit from the different pricing structures in the individual EU member states. Based on
revenue, axicorp is currently the sixth largest parallel importer in Germany.
With a consistent R&D strategy and numerous successful product and company acquisitions and by stepping up its
internationalisation efforts, the Group is continuously optimising its business activities and seeks external growth
opportunities in addition to organic growth.

Contact
Investor Relations & Corporate Communications
Britta Hamberger
Tel.: +49 (0)89 - 64186-233
E-mail: ir@dermapharm.com

2024-06-27 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      Dermapharm Holding SE 

Lil-Dagover-Ring 7
82031 Grünwald
Germany

Phone:        +49 (0)89 64 86-0 
E-mail:       ir@dermapharm.com 
Internet:     ir.dermapharm.de 
ISIN:         DE000A2GS5D8 
WKN:          A2GS5D 
Indices:      SDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 

Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1935093

End of News EQS News Service
===
1935093 2024-06-27 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1935093&application_name=news&site_id=dow_jones%7e%7e%7e43f1f857-252a-44a4-bbde-f4a32f6a5492

END) Dow Jones Newswires

June 27, 2024 12:17 ET (16:17 GMT)